{Reference Type}: Journal Article
{Title}: Multigenic panels in breast cancer: Clinical utility and management of patients with pathogenic variants other than BRCA1/2.
{Author}: Fabi A;Cortesi L;Duranti S;Cordisco EL;Di Leone A;Terribile D;Paris I;de Belvis AG;Orlandi A;Marazzi F;Muratore M;Garganese G;Fuso P;Paoletti F;Dell'Aquila R;Minucci A;Scambia G;Franceschini G;Masetti R;Genuardi M;
{Journal}: Crit Rev Oncol Hematol
{Volume}: 201
{Issue}: 0
{Year}: 2024 Sep 6
{Factor}: 6.625
{DOI}: 10.1016/j.critrevonc.2024.104431
{Abstract}: Multigene panels can analyze high and moderate/intermediate penetrance genes that predispose to breast cancer (BC), providing an opportunity to identify at-risk individuals within affected families. However, considering the complexity of different pathogenic variants and correlated clinical manifestations, a multidisciplinary team is needed to effectively manage BC. A classification of pathogenic variants included in multigene panels was presented in this narrative review to evaluate their clinical utility in BC. Clinical management was discussed for each category and focused on BC, including available evidence regarding the multidisciplinary and integrated management of patients with BC. The integration of both genetic testing and counseling is required for customized decisions in therapeutic strategies and preventative initiatives, as well as for a defined multidisciplinary approach, considering the continuous evolution of guidelines and research in the field.